Playbook for Sustainability Value Creation in Healthcare and Life Sciences

Playbook for Sustainability Value Creation in Healthcare and Life Sciences

There is broad agreement that sustainability can be a source of financial value, yet few investors plan for it. In a recent ERM survey of almost 100 private equity investors in healthcare and life sciences, only 32% reported integrating sustainability into value creation planning. 

Where initiatives are prioritised, they tend to sit in areas with established data and methodologies, such as energy efficiency. This leaves some of the sector’s more significant levers underexplored, for example, meeting demand from customers who prioritise low-carbon alternatives, understanding the market-specific requirements that carry additional weight in tenders, and rethinking packaging to be lighter and more durable in light of the EU Packaging and Packaging Waste Regulation (PPWR). 

The Sustainability Value Creation: Healthcare and Life Sciences Playbook, published by Principles for Responsible Investment (PRI) and developed by ERM, offers practical guidance to private equity investors on how to find the sustainability levers that matter in a portfolio company, quantify their impact on EBITDA and build them into the value creation plan. 

Playbook for Sustainability value creation in Healthcare and Life Sciences

What sets this playbook apart is the combination of perspectives behind it and its sector focus. It brings together the views of sustainability professionals and deal teams, operators within portfolio companies, limited partners and academics. 

The result is a methodology that investors can use at deal screening, in 100-day planning, during the holding period and when preparing for exit. The playbook then applies it to the pharmaceuticals and MedTech sectors, using four portfolio companies as case examples to show, with modelled estimates, how sustainability can create financial value: 

  • Green chemistry: A pharmaceutical contract manufacturer developed an alternative process that cuts upstream solvent use by 90%. Phased adoption is modelled at €33.4m NPV to 2034.
  • Packaging: A MedTech company replaced plastic trays with much lighter pouches. For around €0.4m of capex, the switch models €4.3m NPV to 2029 – a return of around 14x, with payback inside a year.
  • Market access and risk mitigation: A European pharmaceutical company earns around 30% of its revenue from public tenders. Its sustainability credentials protected an estimated €1.4m of net value in Nordic hospital tenders over two years.
  • Circularity and people: A liquid-dosage manufacturer turned plastic waste into a new revenue stream worth €4.8m NPV. Below-target staff turnover avoided an estimated €1.3m of replacement costs in 2024. 

Unlock New Financial Value with Sustainable Investing 

ERM helps clients embed sustainability into investment decisions and advance sustainable finance approaches. We work across the entire financial sector ecosystem, from private markets, financial institutions and corporates, to public and civil society organizations.  

Learn more about ERM’s work in sustainable finance.